Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic HBV vaccination plus pegylated interferon in entecavir-treated chronic hepatitis B
KCT0001395Phase 4Recruiting
- Sponsor
- BMI
- Start
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Hepatitis B vaccine, pegylated interferon alpha and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by BMI. Primary endpoint: HBsAg seroclearance rate. Started Apr 2014; status: recruiting.
02
Drugs
Hepatitis B vaccinepegylated interferon alphaentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on KCT0001395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001395.